Cisplatin/Irinotecan

PreclinicalSmall molecule

Cisplatin/Irinotecan is one of 4 small molecule programs targeting Cancer of the Esophagus. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cancer of the EsophagusTerminated

Cancer of the EsophagusPreclinical

Terminated

Competition

Competitive Landscape

7 competitors in Cancer of the Esophagus

#DrugCompanyPhaseTrials

Modified FOLFOX6

Amgen

Preclinical

1 2

Cisplatin/Irinotecan

GGeorgetown University

Preclinical

1 3

Docetaxel/capecitabine

GGeorgia Center for Oncology Research & Education

Preclinical

1 4

Cisplatin/docetaxel

GGeorgetown University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cancer of the Esophagus1 trial

Molecularly Tailored Therapy for Patients With Metastatic Cancer of the Esophagus and Stomach

Terminated·GGeorgetown University·N/A·NCT02358863·13 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Cisplatin/Irinotecan. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cisplatin/Irinotecan compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cisplatin/Irinotecan. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Georgetown University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: GGeorgetown University

Cisplatin/Irinotecan

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cancer of the Esophagus1 trial

References

Drug Info

Quick Facts

Related News